- Ankylosing Spondylitis: Data Support 6-Month Trial of TNFis
- Three-year follow-up data for patients with ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFis) showed that 6 months of treatment were required to achieve maximum therapeutic benefit and stabilization of physical function, ...
- Secukinumab approved for psoriatic arthritis and ankylosing spondylitis
- Novartis announced January 15 that the FDA has approved secukinumab (Cosentyx, Novartis) for psoriatic arthritis (PsA) and active ankylosing spondylitis.
- United Kingdom Ankylosing Spondylitis Market Highlights 2015 - Research and
- 'UK Ankylosing Spondylitis Market Highlights - 2015', provides UK ankylosing spondylitis market analysis, competitive landscape, and ankylosing spondylitis drug sales forecast in UK.
- Guidelines developed for ankylosing spondylitis treatment
- (HealthDay)—Evidence-based recommendations have been developed for treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). The guidelines were published in the February issue of Arthritis Care ...
- Ankylosing Spondylitis (Bekhterev's Disease) Market - Global API Manufacturers
- Ankylosing Spondylitis (Bekhterev's Disease) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the ...
Ankylosing Spondylitis is described in multiple online sources, as addition to our editors' articles, see section below for printable documents, Ankylosing Spondylitis books and related discussion.
Suggested News Resources
Great care has been taken to prepare the information on this page. Elements of the content come from factual and lexical knowledge databases, realmagick.com library and third-party sources. We appreciate your suggestions and comments on further improvements of the site.